Jane Osbourn: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Cleanup
Filled in 36 bare reference(s) with reFill 2
Line 18: Line 18:
}}
}}


'''Jane Osbourn''' OBE is a scientist and chair of the UK BioIndustry Association.<ref>https://www.bioindustry.org/news-listing/medimmunes-jane-osbourn-announced-as-new-bia-chair.html</ref>
'''Jane Osbourn''' OBE is a scientist and chair of the UK BioIndustry Association.<ref name="auto2">{{Cite web|url=https://www.bioindustry.org/news-listing/medimmunes-jane-osbourn-announced-as-new-bia-chair.html|title=MedImmune’s Jane Osbourn announced as new BIA chair alongside new board appointments|website=www.bioindustry.org}}</ref>


A Natural Sciences graduate of [[Queen's College, Cambridge]], Jane completed several post-graduate qualifications before moving into industry at [[Cambridge Antibody Technology]], that became [[MedImmune]] and [[AstraZeneca]].
A Natural Sciences graduate of [[Queen's College, Cambridge]], Jane completed several post-graduate qualifications before moving into industry at [[Cambridge Antibody Technology]], that became [[MedImmune]] and [[AstraZeneca]].


In the Queen’s [[Birthday Honours]] list of 2019, Jane was awarded the [[Order of the British Empire]] medal for services to "Human Monoclonal Antibody Drug Research and Development and Biotechnology".<ref>https://www.gov.uk/government/news/the-queens-birthday-honours-list-2019</ref>
In the Queen’s [[Birthday Honours]] list of 2019, Jane was awarded the [[Order of the British Empire]] medal for services to "Human Monoclonal Antibody Drug Research and Development and Biotechnology".<ref name="auto">{{Cite web|url=https://www.gov.uk/government/news/the-queens-birthday-honours-list-2019|title=The Queen's Birthday Honours List 2019|website=GOV.UK}}</ref>


==Early life==
==Early life==


Jane was born in [[Bingley]], West Yorkshire and attended [[Bingley_Grammar_School|Bingley Grammar School]]. She is married to John Richer, Research Fellow at Queen’s College, Cambridge.<ref>https://www.queens.cam.ac.uk/visiting-the-college/history/college-facts/fellows-and-presidents/fellows-1900-1999</ref>
Jane was born in [[Bingley]], West Yorkshire and attended [[Bingley_Grammar_School|Bingley Grammar School]]. She is married to John Richer, Research Fellow at Queen’s College, Cambridge.<ref>{{Cite web|url=https://www.queens.cam.ac.uk/visiting-the-college/history/college-facts/fellows-and-presidents/fellows-1900-1999|title=Fellows 1900–1999 &#124; Queens' College|website=www.queens.cam.ac.uk}}</ref>


Jane is sister to [[Anne Osbourn|Professor Anne Osbourn FRS]]<ref>https://nph.onlinelibrary.wiley.com/doi/full/10.1111/nph.13616</ref> who investigates plant natural product [[biosynthesis]].
Jane is sister to [[Anne Osbourn|Professor Anne Osbourn FRS]]<ref>{{Cite journal|url=https://nph.onlinelibrary.wiley.com/doi/abs/10.1111/nph.13616|title=Anne Osbourn|first=Anne|last=Osbourn|date=July 30, 2015|journal=New Phytologist|volume=208|issue=1|pages=23–25|via=Wiley Online Library|doi=10.1111/nph.13616}}</ref> who investigates plant natural product [[biosynthesis]].


==Academic career==
==Academic career==


Jane went on to study at the [[Queen's College, Cambridge]] where she obtained a First Class degree in Natural Sciences (Biochemistry). Jane was recognised in 1986 for playing [[Netball]] at Queens,<ref name="Queen’s College Record, 1986 - page 21">https://www.queens.cam.ac.uk/files/publicationFiles/queens-college-1986ocr.pdf</ref> and was also awarded both a third year Foundation Scholarship and The Henry Mosseri prize.<ref>https://issuu.com/queenscollegecam/docs/queens_-college-1988ocr/19</ref>
Jane went on to study at the [[Queen's College, Cambridge]] where she obtained a First Class degree in Natural Sciences (Biochemistry). Jane was recognised in 1986 for playing [[Netball]] at Queens,<ref name="Queen’s College Record, 1986 - page 21">https://www.queens.cam.ac.uk/files/publicationFiles/queens-college-1986ocr.pdf</ref> and was also awarded both a third year Foundation Scholarship and The Henry Mosseri prize.<ref>{{Cite web|url=https://issuu.com/queenscollegecam/docs/queens_-college-1988ocr/19|title=The Record 1988|website=Issuu}}</ref>


She then went on to complete a PhD at the [[John Innes Centre]] for Plant Science Research in [[Norwich]] which resulted in the publication of “''Evidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein''”<ref>https://www.ncbi.nlm.nih.gov/pubmed/2773325</ref>. Following this Jane completed a post-doctoral position at [[Rutgers University]], [[New Jersey]], undertaking research directed towards clarification of the sequence elements responsible for the translational enhancement effect conferred by the 5' untranslated region of Tobacco Mosaic Virus known as omega.<ref>https://www.researchgate.net/publication/20916554_Complementation_of_coat_protein-defective_TMV_mutants_in_transgenic_tobacco_plants_expressing_TMV_coat_protein</ref>
She then went on to complete a PhD at the [[John Innes Centre]] for Plant Science Research in [[Norwich]] which resulted in the publication of “''Evidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein''”<ref>{{Cite journal|url=https://www.ncbi.nlm.nih.gov/pubmed/2773325|title=Evidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein|first1=J. K.|last1=Osbourn|first2=J. W.|last2=Watts|first3=R. N.|last3=Beachy|first4=T. M.|last4=Wilson|date=September 30, 1989|journal=Virology|volume=172|issue=1|pages=370–373|via=PubMed|doi=10.1016/0042-6822(89)90143-8|pmid=2773325}}</ref>. Following this Jane completed a post-doctoral position at [[Rutgers University]], [[New Jersey]], undertaking research directed towards clarification of the sequence elements responsible for the translational enhancement effect conferred by the 5' untranslated region of Tobacco Mosaic Virus known as omega.<ref>{{Cite web|url=https://www.researchgate.net/publication/20916554_Complementation_of_coat_protein-defective_TMV_mutants_in_transgenic_tobacco_plants_expressing_TMV_coat_protein|title=Complementation of coat protein-defective TMV mutants in transgenic tobacco plants expressing TMV coat protein &#124; Jane K. Osbourn &#124; Request PDF|website=ResearchGate}}</ref>


Jane then moved into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.<ref>https://danilposh.com/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe/</ref>
Jane then moved into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.<ref>{{Cite web|url=https://danilposh.com/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe/|title=Dr Jane Osbourn of AstraZeneca and UK BioIndustry Affiliation thanks colleagues as she is made an OBE|date=June 7, 2019|website=danilposh}}</ref>


== Career in industry==
== Career in industry==
In 1993 she moved to a small, Cambridge-based start-up biotechnology company called [[Cambridge Antibody Technology]]<ref>https://www.cambridgeindependent.co.uk/business/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe-9072863/</ref> - a company co-founded by Sir [[Greg Winter]] and Dr [[David_Chiswell|David Chiswell MBE]]. CAT, as it was called, would be create the technology that discovered some of the world's highest selling drugs, for example, [[Humira]].<ref>https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868</ref> Jane was both lead and co-author on several papers to come out of CAT.
In 1993 she moved to a small, Cambridge-based start-up biotechnology company called [[Cambridge Antibody Technology]]<ref name="auto3">https://www.cambridgeindependent.co.uk/business/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe-9072863/</ref> - a company co-founded by Sir [[Greg Winter]] and Dr [[David_Chiswell|David Chiswell MBE]]. CAT, as it was called, would be create the technology that discovered some of the world's highest selling drugs, for example, [[Humira]].<ref>{{Cite web|url=https://www.genengnews.com/a-lists/the-top-15-best-selling-drugs-of-2016/|title=The Top 15 Best-Selling Drugs of 2016|date=March 6, 2017}}</ref> Jane was both lead and co-author on several papers to come out of CAT.


She was the key author of several, high impact scientific papers including “''Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library''”<ref>Nature, 1996 - https://www.nature.com/articles/nbt0396-309</ref> and “''Human Antibodies by Design''”<ref>https://www.ncbi.nlm.nih.gov/pubmed/9624683</ref> and co-author of several others pertaining to the use of phage display for antibody discovery and development.<ref>https://www.ncbi.nlm.nih.gov/pubmed/?term=Osbourn%20JK%5BAuthor%5D&cauthor=true&cauthor_uid=11968489</ref>
She was the key author of several, high impact scientific papers including “''Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library''”<ref>Nature, 1996 - https://www.nature.com/articles/nbt0396-309</ref> and “''Human Antibodies by Design''”<ref>{{Cite journal|url=https://www.ncbi.nlm.nih.gov/pubmed/9624683|title=Human antibodies by design|first1=T. J.|last1=Vaughan|first2=J. K.|last2=Osbourn|first3=P. R.|last3=Tempest|date=June 30, 1998|journal=Nature Biotechnology|volume=16|issue=6|pages=535–539|via=PubMed|doi=10.1038/nbt0698-535|pmid=9624683}}</ref> and co-author of several others pertaining to the use of phage display for antibody discovery and development.<ref>{{Cite web|url=https://www.ncbi.nlm.nih.gov/pubmed/?term=Osbourn+JK%5BAuthor%5D&cauthor=true&cauthor_uid=11968489|title=Error encountered - PubMed - NCBI|website=www.ncbi.nlm.nih.gov}}</ref>


Jane is listed as an inventor on several patents:
Jane is listed as an inventor on several patents:
* EP0906571 - Labelling and selection of molecules<ref>https://patents.google.com/patent/EP0906571A1</ref>
* EP0906571 - Labelling and selection of molecules<ref>{{Cite web|url=https://patents.google.com/patent/EP0906571A1/en|title=Labelling and selection of molecules}}</ref>
* US5994519A - Labelling and selection of molecules<ref>https://patents.google.com/patent/US5994519</ref>
* US5994519A - Labelling and selection of molecules<ref>{{Cite web|url=https://patents.google.com/patent/US5994519A/en|title=Labelling and selection of molecules}}</ref>
* EP1353180B1 - Labelling and selection of molecules<ref>https://patents.google.com/patent/EP1353180B1</ref>
* EP1353180B1 - Labelling and selection of molecules<ref>{{Cite web|url=https://patents.google.com/patent/EP1353180B1/en|title=Labelling and selection of molecules}}</ref>
* EP0865492B1 - Specific binding members for human carcinoembryonic antigen, materials and methods<ref>https://patents.google.com/patent/EP0865492B1</ref>
* EP0865492B1 - Specific binding members for human carcinoembryonic antigen, materials and methods<ref>{{Cite web|url=https://patents.google.com/patent/EP0865492B1/en|title=Specific binding members for human carcinoembryonic antigen, materials and methods}}</ref>
* US7074557 - Ribosome Display<ref>https://patents.google.com/patent/US7074557</ref>
* US7074557 - Ribosome Display<ref>{{Cite web|url=https://patents.google.com/patent/US7074557B2/en|title=Ribosome display}}</ref>
* EP1268766 - Improvements to Ribosome Display<ref>https://register.epo.org/espacenet/regviewer?AP=01914058&CY=EP&LG=en&DB=REG</ref>
* EP1268766 - Improvements to Ribosome Display<ref>{{Cite web|url=https://register.epo.org/espacenet/regviewer?AP=01914058&CY=EP&LG=en&DB=REG|title=About this file - European Patent Register|website=register.epo.org}}</ref>
* WO2001075097A2 - Improvements to Ribosome Display<ref>https://patents.google.com/patent/WO2001075097A2</ref>
* WO2001075097A2 - Improvements to Ribosome Display<ref>{{Cite web|url=https://patents.google.com/patent/WO2001075097A2/en|title=Improvements to ribosome display}}</ref>


She also created a technique to assist with the discovery of proximity-guided selection of antibodies, so called Proximol.<ref>https://www.ncbi.nlm.nih.gov/pubmed/11968489</ref>
She also created a technique to assist with the discovery of proximity-guided selection of antibodies, so called Proximol.<ref>{{Cite journal|url=https://www.ncbi.nlm.nih.gov/pubmed/11968489|title=Proximity-guided (ProxiMol) antibody selection|first=Jane K.|last=Osbourn|date=July 30, 2002|journal=Methods in Molecular Biology (Clifton, N.J.)|volume=178|pages=201–205|via=PubMed|pmid=11968489}}</ref>


CAT was acquired by AstraZeneca in 2006<ref>http://news.bbc.co.uk/1/hi/business/4771615.stm</ref> and in the following year was merged with a US-based company called MedImmune <ref>https://web.archive.org/web/20100113110854/http://astrazeneca.com/media/latest-press-releases/2007/5336?itemId=3891476</ref> to form AstraZeneca’s global biologics R&D arm. During this time Jane began to speak about opportunities for diversity in science.<ref>https://www.independent.co.uk/news/education/how-can-we-encourage-more-girls-to-study-science-9913799.html</ref>
CAT was acquired by AstraZeneca in 2006<ref>{{Cite web|url=http://news.bbc.co.uk/2/hi/business/4771615.stm|title=AstraZeneca to buy CAT for £702m|date=May 15, 2006|via=news.bbc.co.uk}}</ref> and in the following year was merged with a US-based company called MedImmune <ref>https://web.archive.org/web/20100113110854/http://astrazeneca.com/media/latest-press-releases/2007/5336?itemId=3891476</ref> to form AstraZeneca’s global biologics R&D arm. During this time Jane began to speak about opportunities for diversity in science.<ref>{{Cite web|url=http://www.independent.co.uk/news/education/how-can-we-encourage-more-girls-to-study-science-9913799.html|title=How can we encourage more girls to study science?|date=December 9, 2014|website=The Independent}}</ref>


In 2013, AstraZeneca announced it’s decision to relocate it’s headquarters to [[Cambridge]], UK<ref>https://www.bbc.co.uk/news/uk-england-22949623</ref>. Some{{who|date=July 2019}} have observed that Jane had an influence over this decision.<ref>http://www.creativeplaces.com/thinking/articles/open-innovation/</ref>
In 2013, AstraZeneca announced it’s decision to relocate it’s headquarters to [[Cambridge]], UK<ref>{{Cite web|url=https://www.bbc.com/news/uk-england-22949623|title=Cambridge HQ for pharmaceutical firm|date=June 18, 2013|via=www.bbc.co.uk}}</ref>. Some{{who|date=July 2019}} have observed that Jane had an influence over this decision.<ref>{{Cite web|url=http://www.creativeplaces.com/thinking/articles/open-innovation/|title=Creative Places &#124; Open Innovation|website=www.creativeplaces.com}}</ref>


In February 2019, it was announced that Jane would be leaving AstraZeneca.<ref>https://www.thepharmaletter.com/article/bia-chairwomen-jane-osbourn-to-leave-astrazeneca</ref>
In February 2019, it was announced that Jane would be leaving AstraZeneca.<ref>{{Cite web|url=https://www.thepharmaletter.com/article/bia-chairwomen-jane-osbourn-to-leave-astrazeneca|title=BIA chairwomen Jane Osbourn to leave AstraZeneca|website=www.thepharmaletter.com}}</ref>


== Recognition==
== Recognition==
Jane’s early interest in science has grown into a passion for science education, supporting and championing life science education programmes and she is established as an advisor and mentor to many young researchers in the life science sector. She has been acknowledged by a number of different pharmaceutical media groups for these qualities.
Jane’s early interest in science has grown into a passion for science education, supporting and championing life science education programmes and she is established as an advisor and mentor to many young researchers in the life science sector. She has been acknowledged by a number of different pharmaceutical media groups for these qualities.


* Jane has been recognised in two of their Movers and Shakers lists - BioBeat 50 Movers and Shakers in BioBusiness 2014.<ref>http://mws-consulting.co.uk/downloads/50_Movers_and_Shakers_in_BioBusiness_2014.pdf</ref><ref>https://www.mws-consulting.co.uk/wordpress/wp-content/uploads/2015/02/50-Movers-and-Shakers-in-BioBusiness-2016-final.pdf</ref> BioBeat is an organisation that connects entrepreneurs with the leaders in biotech.<ref>https://www.mws-consulting.co.uk/biobeat/</ref>
* Jane has been recognised in two of their Movers and Shakers lists - BioBeat 50 Movers and Shakers in BioBusiness 2014.<ref>http://mws-consulting.co.uk/downloads/50_Movers_and_Shakers_in_BioBusiness_2014.pdf</ref><ref>https://www.mws-consulting.co.uk/wordpress/wp-content/uploads/2015/02/50-Movers-and-Shakers-in-BioBusiness-2016-final.pdf</ref> BioBeat is an organisation that connects entrepreneurs with the leaders in biotech.<ref>{{Cite web|url=https://www.mws-consulting.co.uk/biobeat/|title=Biobeat 2018}}</ref>
* In 2016 Jane was recognised in the PharmaVoice 100 researchers and scientists.<ref>https://www.pharmavoice.com/article/2016-pharmavoice100-researchers-and-scientists/</ref>.PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals<ref>https://www.pharmavoice.com/about-us/</ref>
* In 2016 Jane was recognised in the PharmaVoice 100 researchers and scientists.<ref>{{Cite web|url=https://www.pharmavoice.com/article/2016-pharmavoice100-researchers-and-scientists/|title=The 2016 PharmaVOICE 100 Researchers and Scientists}}</ref>.PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals<ref>{{Cite web|url=https://www.pharmavoice.com/about-us/|title=About Us}}</ref>
* In 2016, Fierce Pharma’s “Fierce Women in Biopharma” recognised Jane as one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.<ref>https://www.fiercepharma.com/special-report/fierce-women-biopharma-2016</ref> FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval.<ref>https://www.fiercepharma.com/about-us</ref>
* In 2016, Fierce Pharma’s “Fierce Women in Biopharma” recognised Jane as one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.<ref>{{Cite web|url=https://www.fiercepharma.com/special-report/fierce-women-biopharma-2016|title=Fierce Women in Biopharma 2016|website=FiercePharma}}</ref> FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval.<ref>{{Cite web|url=https://www.fiercepharma.com/about-us|title=About Us|website=FiercePharma}}</ref>


In 2014 Jane was elected to join the board of the BioIndustry Association, becoming Chair in 2016;<ref>https://www.bioindustry.org/news-listing/medimmunes-jane-osbourn-announced-as-new-bia-chair.html</ref> and in this role she has been working to support the development of the biotechnology sector in the UK. As part of this Jane is also a Director of Babraham Bioscience Technologies<ref>https://beta.companieshouse.gov.uk/company/03241492/officers</ref> and a Director of Cambridge Enterprise, the technology transfer organisation for University of Cambridge.<ref>https://beta.companieshouse.gov.uk/company/01069886/filing-history?page=2</ref>
In 2014 Jane was elected to join the board of the BioIndustry Association, becoming Chair in 2016;<ref name="auto2"/> and in this role she has been working to support the development of the biotechnology sector in the UK. As part of this Jane is also a Director of Babraham Bioscience Technologies<ref>{{Cite web|url=https://beta.companieshouse.gov.uk/company/03241492/officers|title=BABRAHAM BIOSCIENCE TECHNOLOGIES LIMITED - Officers (free information from Companies House)|website=beta.companieshouse.gov.uk}}</ref> and a Director of Cambridge Enterprise, the technology transfer organisation for University of Cambridge.<ref>{{Cite web|url=https://beta.companieshouse.gov.uk/company/01069886/filing-history?page=2|title=CAMBRIDGE ENTERPRISE LIMITED - Filing history (free information from Companies House)|website=beta.companieshouse.gov.uk}}</ref>


Jane has presented at a number of parliamentary Select Committees. At the Business, Innovation and Skills Committee, on Tuesday 13 May 2014, she gave evidence on behalf of AstraZeneca as they faced a takeover from [[Pfizer]].<ref>https://parliamentlive.tv/event/index/c0034f82-65b8-4467-bb51-cee77a165389?in=11:26:59&out=12:27:00</ref><ref>http://data.parliament.uk/writtenevidence/committeeevidence.svc/evidencedocument/business-innovation-and-skills-committee/the-future-of-astrazeneca/oral/9564.html</ref>
Jane has presented at a number of parliamentary Select Committees. At the Business, Innovation and Skills Committee, on Tuesday 13 May 2014, she gave evidence on behalf of AstraZeneca as they faced a takeover from [[Pfizer]].<ref>{{Cite web|url=https://parliamentlive.tv/event/index/c0034f82-65b8-4467-bb51-cee77a165389?in=11:26:59&out=12:27:00|title=Parliamentlive.tv|website=parliamentlive.tv}}</ref><ref>{{Cite web|url=http://data.parliament.uk/writtenevidence/committeeevidence.svc/evidencedocument/business-innovation-and-skills-committee/the-future-of-astrazeneca/oral/9564.html|title=[Committee name]|website=data.parliament.uk}}</ref>


Later that year, on 1st July 2014, Jane gave evidence to the Science and Technology Select Committee: Priorities for Scientific Research.<ref name="Transcript, page 75">https://www.parliament.uk/documents/lords-committees/science-technology/2025Prioritiesforscientificresearch/2025Prioritiesforscientificresearchevidence.pdf</ref>
Later that year, on 1st July 2014, Jane gave evidence to the Science and Technology Select Committee: Priorities for Scientific Research.<ref name="Transcript, page 75">https://www.parliament.uk/documents/lords-committees/science-technology/2025Prioritiesforscientificresearch/2025Prioritiesforscientificresearchevidence.pdf</ref>


Jane has also has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel.<ref>https://www.businessweekly.co.uk/business-awards/awards-news/17982-az-and-medimmune-spearhead-biotech-judging</ref>
Jane has also has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel.<ref>{{Cite web|url=https://www.businessweekly.co.uk/business-awards/awards-news/17982-az-and-medimmune-spearhead-biotech-judging|title=AZ and MedImmune to spearhead biotech judging &#124; Business Weekly &#124; Technology News &#124; Business news &#124; Cambridge and the East of England|website=www.businessweekly.co.uk}}</ref>


In 2018 the [[Nobel Prize]] for Chemistry was awarded jointly to [[Gregory_Winter|Sir Greg Winter]], [[George Smith]] and [[Frances Arnold]]. Sir Greg Winter received his award for the phage display of peptides and antibodies.<ref>https://www.nobelprize.org/prizes/chemistry/2018/winter/facts/</ref> Sir Greg and [[David Chiswell]] founded [[Cambridge Antibody Technology]] to exploit this science. Jane says of this time “''There was a cohort of really able intellect in Cambridge – in CAT and other companies, in the [[Medical_Research_Council_(United_Kingdom)|MRC]] [[Laboratory_of_Molecular_Biology|LMB]] and in the University – and what happened was a condensation of that focus… Once we decided to make phage display work, we set some really tough goals and then just got on with it''.”<ref>https://www.cam.ac.uk/antibodies</ref> To recognise Jane’s contribution to the prize, she, along with [[David Chiswell]] and [[John McCafferty]] accompanied Sir Greg to the Nobel ceremony.<ref>https://www.cam.ac.uk/antibodies</ref>
In 2018 the [[Nobel Prize]] for Chemistry was awarded jointly to [[Gregory_Winter|Sir Greg Winter]], [[George Smith]] and [[Frances Arnold]]. Sir Greg Winter received his award for the phage display of peptides and antibodies.<ref>{{Cite web|url=https://www.nobelprize.org/prizes/chemistry/2018/winter/facts/|title=The Nobel Prize in Chemistry 2018|website=NobelPrize.org}}</ref> Sir Greg and [[David Chiswell]] founded [[Cambridge Antibody Technology]] to exploit this science. Jane says of this time “''There was a cohort of really able intellect in Cambridge – in CAT and other companies, in the [[Medical_Research_Council_(United_Kingdom)|MRC]] [[Laboratory_of_Molecular_Biology|LMB]] and in the University – and what happened was a condensation of that focus… Once we decided to make phage display work, we set some really tough goals and then just got on with it''.”<ref name="auto1">{{Cite web|url=https://www.cam.ac.uk/antibodies|title="A very Cambridge story"|first=Louise|last=Walsh|date=March 20, 2019|website=University of Cambridge}}</ref> To recognise Jane’s contribution to the prize, she, along with [[David Chiswell]] and [[John McCafferty]] accompanied Sir Greg to the Nobel ceremony.<ref name="auto1"/>


On 7 June 2019 Jane was awarded an OBE for services to Human Monoclonal Antibody Drug Research and Development and Biotechnology.<ref>https://www.gov.uk/government/news/the-queens-birthday-honours-list-2019</ref> CEO of [[AstraZeneca]], [[Pascal Soriot]], said of the award "''On behalf of AstraZeneca, I am delighted to congratulate Dr Jane Osbourn for her award of an OBE in recognition of her services to human [[monoclonal antibody]] drug research and development and [[biotechnology]]. This well-deserved honour reflects her contribution to biopharmaceutical science over more than 25 years, from [[Cambridge Antibody Technology]] to AstraZeneca and [[MedImmune]]. Jane’s leadership in UK life sciences includes championing the biotech sector through her position as chair of the BIA and contributing to the growth of the UK’s scientific ecosystem. I would also like to recognise her authentic commitment to building skills through [[Science,_technology,_engineering,_and_mathematics|STEM]] and education outreach, in particular for women in science''".<ref>https://www.cambridgeindependent.co.uk/business/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe-9072863/</ref>
On 7 June 2019 Jane was awarded an OBE for services to Human Monoclonal Antibody Drug Research and Development and Biotechnology.<ref name="auto"/> CEO of [[AstraZeneca]], [[Pascal Soriot]], said of the award "''On behalf of AstraZeneca, I am delighted to congratulate Dr Jane Osbourn for her award of an OBE in recognition of her services to human [[monoclonal antibody]] drug research and development and [[biotechnology]]. This well-deserved honour reflects her contribution to biopharmaceutical science over more than 25 years, from [[Cambridge Antibody Technology]] to AstraZeneca and [[MedImmune]]. Jane’s leadership in UK life sciences includes championing the biotech sector through her position as chair of the BIA and contributing to the growth of the UK’s scientific ecosystem. I would also like to recognise her authentic commitment to building skills through [[Science,_technology,_engineering,_and_mathematics|STEM]] and education outreach, in particular for women in science''".<ref name="auto3"/>


==References==
==References==

Revision as of 14:22, 30 July 2019

Jane Osbourn
OBE
File:Jane Osbourn 2014.jpg
'
Born
Jane Katherine Osbourn

Bingley, West Yorkshire, England
CitizenshipUnited Kingdom
EducationBingley Grammar School
Queen's College, Cambridge (BSc)
John Innes Centre, Norwich (PhD)
Known forAntibody engineering
Cambridge Antibody Technology
MedImmune
AstraZeneca
STEM
Scientific career
FieldsBiotechnology
ThesisEvidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein (1991)
Doctoral advisorT. Michael A. Wilson

Jane Osbourn OBE is a scientist and chair of the UK BioIndustry Association.[1]

A Natural Sciences graduate of Queen's College, Cambridge, Jane completed several post-graduate qualifications before moving into industry at Cambridge Antibody Technology, that became MedImmune and AstraZeneca.

In the Queen’s Birthday Honours list of 2019, Jane was awarded the Order of the British Empire medal for services to "Human Monoclonal Antibody Drug Research and Development and Biotechnology".[2]

Early life

Jane was born in Bingley, West Yorkshire and attended Bingley Grammar School. She is married to John Richer, Research Fellow at Queen’s College, Cambridge.[3]

Jane is sister to Professor Anne Osbourn FRS[4] who investigates plant natural product biosynthesis.

Academic career

Jane went on to study at the Queen's College, Cambridge where she obtained a First Class degree in Natural Sciences (Biochemistry). Jane was recognised in 1986 for playing Netball at Queens,[5] and was also awarded both a third year Foundation Scholarship and The Henry Mosseri prize.[6]

She then went on to complete a PhD at the John Innes Centre for Plant Science Research in Norwich which resulted in the publication of “Evidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein”[7]. Following this Jane completed a post-doctoral position at Rutgers University, New Jersey, undertaking research directed towards clarification of the sequence elements responsible for the translational enhancement effect conferred by the 5' untranslated region of Tobacco Mosaic Virus known as omega.[8]

Jane then moved into medical research through a British Heart Foundation Post-Doctoral Fellowship at the Department of Medicine at Addenbrooke's Hospital in Cambridge.[9]

Career in industry

In 1993 she moved to a small, Cambridge-based start-up biotechnology company called Cambridge Antibody Technology[10] - a company co-founded by Sir Greg Winter and Dr David Chiswell MBE. CAT, as it was called, would be create the technology that discovered some of the world's highest selling drugs, for example, Humira.[11] Jane was both lead and co-author on several papers to come out of CAT.

She was the key author of several, high impact scientific papers including “Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library”[12] and “Human Antibodies by Design”[13] and co-author of several others pertaining to the use of phage display for antibody discovery and development.[14]

Jane is listed as an inventor on several patents:

  • EP0906571 - Labelling and selection of molecules[15]
  • US5994519A - Labelling and selection of molecules[16]
  • EP1353180B1 - Labelling and selection of molecules[17]
  • EP0865492B1 - Specific binding members for human carcinoembryonic antigen, materials and methods[18]
  • US7074557 - Ribosome Display[19]
  • EP1268766 - Improvements to Ribosome Display[20]
  • WO2001075097A2 - Improvements to Ribosome Display[21]

She also created a technique to assist with the discovery of proximity-guided selection of antibodies, so called Proximol.[22]

CAT was acquired by AstraZeneca in 2006[23] and in the following year was merged with a US-based company called MedImmune [24] to form AstraZeneca’s global biologics R&D arm. During this time Jane began to speak about opportunities for diversity in science.[25]

In 2013, AstraZeneca announced it’s decision to relocate it’s headquarters to Cambridge, UK[26]. Some[who?] have observed that Jane had an influence over this decision.[27]

In February 2019, it was announced that Jane would be leaving AstraZeneca.[28]

Recognition

Jane’s early interest in science has grown into a passion for science education, supporting and championing life science education programmes and she is established as an advisor and mentor to many young researchers in the life science sector. She has been acknowledged by a number of different pharmaceutical media groups for these qualities.

  • Jane has been recognised in two of their Movers and Shakers lists - BioBeat 50 Movers and Shakers in BioBusiness 2014.[29][30] BioBeat is an organisation that connects entrepreneurs with the leaders in biotech.[31]
  • In 2016 Jane was recognised in the PharmaVoice 100 researchers and scientists.[32].PharmaVOICE is a resource for life-sciences executives and other healthcare-service related professionals[33]
  • In 2016, Fierce Pharma’s “Fierce Women in Biopharma” recognised Jane as one of 15 women in the global industry noteworthy for their leadership, providing mentorship and helping increase opportunities for women in science.[34] FierceBiotech and its family of publications provide end-to-end coverage of biotech and medtech, from pre-clinical science through clinical testing and regulatory approval.[35]

In 2014 Jane was elected to join the board of the BioIndustry Association, becoming Chair in 2016;[1] and in this role she has been working to support the development of the biotechnology sector in the UK. As part of this Jane is also a Director of Babraham Bioscience Technologies[36] and a Director of Cambridge Enterprise, the technology transfer organisation for University of Cambridge.[37]

Jane has presented at a number of parliamentary Select Committees. At the Business, Innovation and Skills Committee, on Tuesday 13 May 2014, she gave evidence on behalf of AstraZeneca as they faced a takeover from Pfizer.[38][39]

Later that year, on 1st July 2014, Jane gave evidence to the Science and Technology Select Committee: Priorities for Scientific Research.[40]

Jane has also has previously served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel.[41]

In 2018 the Nobel Prize for Chemistry was awarded jointly to Sir Greg Winter, George Smith and Frances Arnold. Sir Greg Winter received his award for the phage display of peptides and antibodies.[42] Sir Greg and David Chiswell founded Cambridge Antibody Technology to exploit this science. Jane says of this time “There was a cohort of really able intellect in Cambridge – in CAT and other companies, in the MRC LMB and in the University – and what happened was a condensation of that focus… Once we decided to make phage display work, we set some really tough goals and then just got on with it.”[43] To recognise Jane’s contribution to the prize, she, along with David Chiswell and John McCafferty accompanied Sir Greg to the Nobel ceremony.[43]

On 7 June 2019 Jane was awarded an OBE for services to Human Monoclonal Antibody Drug Research and Development and Biotechnology.[2] CEO of AstraZeneca, Pascal Soriot, said of the award "On behalf of AstraZeneca, I am delighted to congratulate Dr Jane Osbourn for her award of an OBE in recognition of her services to human monoclonal antibody drug research and development and biotechnology. This well-deserved honour reflects her contribution to biopharmaceutical science over more than 25 years, from Cambridge Antibody Technology to AstraZeneca and MedImmune. Jane’s leadership in UK life sciences includes championing the biotech sector through her position as chair of the BIA and contributing to the growth of the UK’s scientific ecosystem. I would also like to recognise her authentic commitment to building skills through STEM and education outreach, in particular for women in science".[10]

References

  1. ^ a b "MedImmune's Jane Osbourn announced as new BIA chair alongside new board appointments". www.bioindustry.org.
  2. ^ a b "The Queen's Birthday Honours List 2019". GOV.UK.
  3. ^ "Fellows 1900–1999 | Queens' College". www.queens.cam.ac.uk.
  4. ^ Osbourn, Anne (July 30, 2015). "Anne Osbourn". New Phytologist. 208 (1): 23–25. doi:10.1111/nph.13616 – via Wiley Online Library.
  5. ^ https://www.queens.cam.ac.uk/files/publicationFiles/queens-college-1986ocr.pdf
  6. ^ "The Record 1988". Issuu.
  7. ^ Osbourn, J. K.; Watts, J. W.; Beachy, R. N.; Wilson, T. M. (September 30, 1989). "Evidence that nucleocapsid disassembly and a later step in virus replication are inhibited in transgenic tobacco protoplasts expressing TMV coat protein". Virology. 172 (1): 370–373. doi:10.1016/0042-6822(89)90143-8. PMID 2773325 – via PubMed.
  8. ^ "Complementation of coat protein-defective TMV mutants in transgenic tobacco plants expressing TMV coat protein | Jane K. Osbourn | Request PDF". ResearchGate.
  9. ^ "Dr Jane Osbourn of AstraZeneca and UK BioIndustry Affiliation thanks colleagues as she is made an OBE". danilposh. June 7, 2019.
  10. ^ a b https://www.cambridgeindependent.co.uk/business/dr-jane-osbourn-of-astrazeneca-and-uk-bioindustry-association-thanks-colleagues-as-she-is-made-an-obe-9072863/
  11. ^ "The Top 15 Best-Selling Drugs of 2016". March 6, 2017.
  12. ^ Nature, 1996 - https://www.nature.com/articles/nbt0396-309
  13. ^ Vaughan, T. J.; Osbourn, J. K.; Tempest, P. R. (June 30, 1998). "Human antibodies by design". Nature Biotechnology. 16 (6): 535–539. doi:10.1038/nbt0698-535. PMID 9624683 – via PubMed.
  14. ^ "Error encountered - PubMed - NCBI". www.ncbi.nlm.nih.gov.
  15. ^ "Labelling and selection of molecules".
  16. ^ "Labelling and selection of molecules".
  17. ^ "Labelling and selection of molecules".
  18. ^ "Specific binding members for human carcinoembryonic antigen, materials and methods".
  19. ^ "Ribosome display".
  20. ^ "About this file - European Patent Register". register.epo.org.
  21. ^ "Improvements to ribosome display".
  22. ^ Osbourn, Jane K. (July 30, 2002). "Proximity-guided (ProxiMol) antibody selection". Methods in Molecular Biology (Clifton, N.J.). 178: 201–205. PMID 11968489 – via PubMed.
  23. ^ "AstraZeneca to buy CAT for £702m". May 15, 2006 – via news.bbc.co.uk.
  24. ^ https://web.archive.org/web/20100113110854/http://astrazeneca.com/media/latest-press-releases/2007/5336?itemId=3891476
  25. ^ "How can we encourage more girls to study science?". The Independent. December 9, 2014.
  26. ^ "Cambridge HQ for pharmaceutical firm". June 18, 2013 – via www.bbc.co.uk.
  27. ^ "Creative Places | Open Innovation". www.creativeplaces.com.
  28. ^ "BIA chairwomen Jane Osbourn to leave AstraZeneca". www.thepharmaletter.com.
  29. ^ http://mws-consulting.co.uk/downloads/50_Movers_and_Shakers_in_BioBusiness_2014.pdf
  30. ^ https://www.mws-consulting.co.uk/wordpress/wp-content/uploads/2015/02/50-Movers-and-Shakers-in-BioBusiness-2016-final.pdf
  31. ^ "Biobeat 2018".
  32. ^ "The 2016 PharmaVOICE 100 Researchers and Scientists".
  33. ^ "About Us".
  34. ^ "Fierce Women in Biopharma 2016". FiercePharma.
  35. ^ "About Us". FiercePharma.
  36. ^ "BABRAHAM BIOSCIENCE TECHNOLOGIES LIMITED - Officers (free information from Companies House)". beta.companieshouse.gov.uk.
  37. ^ "CAMBRIDGE ENTERPRISE LIMITED - Filing history (free information from Companies House)". beta.companieshouse.gov.uk.
  38. ^ "Parliamentlive.tv". parliamentlive.tv.
  39. ^ "[Committee name]". data.parliament.uk.
  40. ^ https://www.parliament.uk/documents/lords-committees/science-technology/2025Prioritiesforscientificresearch/2025Prioritiesforscientificresearchevidence.pdf
  41. ^ "AZ and MedImmune to spearhead biotech judging | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk.
  42. ^ "The Nobel Prize in Chemistry 2018". NobelPrize.org.
  43. ^ a b Walsh, Louise (March 20, 2019). ""A very Cambridge story"". University of Cambridge.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Jane_Osbourn&oldid=908562425"